Engage:BDR provides revenue update

Published 01-APR-2019 11:12 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Engage:BDR (ASX:EN1) has released a revenue update for Q1 2019.

At the end of January 2019, EN1 raised A$700k in a placement to existing shareholders (and shortly after), a draw down from its existing convertible notes facility of US$720k.

This capital was raised with intention of activating dormant publishers which were strong contributors to EN1’s programmatic business over the past two years.

Approximately A$1.1 million was deployed during February 2019, publisher activation took nearly 3-4 weeks in some instances. On 18th March 2019, management reported the initial results of the activity was yielding around US$20k revenue per day.

Management expected full volume capacity with all publishers within 30 to 60 days from 18 March 2019. At that time, revenue expectation was US$30k per day.

EN1 will begin testing its new AI technology to reduce margins and increase sell-through margins to accommodate high gross profits.

Historically, the fourth quarter of the year is typically the largest for advertising companies in the US from a revenue standpoint.

EN1 expected Q4 2018 to be strong, but due to limited capital key publisher activation was down during this time. As a result, average programmatic advertising revenue during this period was about US$16k per day.

New results

Results over the last seven days demonstrate an increase in daily revenue of about 40%, from US$20k to US$28k per day. Gross margins have sustained ~41%, with management still to test its AI margin optimisation tech. This is expected in the next two weeks.

This proprietary auction optimisation technology is intended to deliver stronger revenues and sell-through on existing supply and demand, while achieving stronger results for EN1’s brands and publishers.

Revenue averages over a shorter period (less than the past seven days) show significantly stronger results over 40% growth to US$28k per day. The company will update the market shortly with these new results once they’re statistically relevant.

End of year and quarter daily revenues generally trend higher than overall daily averages, the market should expect these recent figures to be higher than daily averages over the entire first quarter.

The current daily average is about 75% greater than Q4 2018 daily averages – EN1 feels this is a strong indication for what to expect for 2019.

In summary

As mentioned above, the company expects publishers to be operating at full capacity over the next 30-60 days.

Revenue estimates at full-capacity have now increased to 25% at US$37.5k per day, up from US$30k (or A$42k). Gross profit margins are expected to be in the 35-40% range, with the current yield at ~41% (around double of what the industry average is).

Naturally, revenue growth could enable EN1 to generate more gross profit. The company’s primary objective is to return to profitability, with 2019 shaping up as a pivotal year for EN1.

The company will update the market on further activities and revenue as they develop.

tags

TECH REVENUE


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X